Alvotech reported $586M of revenue over the trailing twelve months, +20% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $586M (to FY2025). Net income: $28M, trailing twelve months to FY2025. Free cash flow: −$115M, trailing twelve months to FY2025. Operating margin: 13%, trailing twelve months to FY2025.

ALVOAlvotech

Healthcare

$5.79-27% 1Y

$5.79

$3.0052 weeks$8.98

ALVO as reported

Alvotech reported $586M of revenue over the trailing twelve months, +20% on the year before. 10 reported series are charted on this page, each one as filed.

$586M

Revenue, trailing twelve months · to FY2025 · +20% against the twelve months before

Net income: $28M
Net income · −112% year on year · trailing twelve months to FY2025
Free cash flow: −$115M
Free cash flow · −61% year on year · trailing twelve months to FY2025
Operating margin: 13%
Operating margin · trailing twelve months to FY2025

Details›

Every series Ryufin has for ALVO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$586M	+20%	FY2025
Net income	$28M	−112%	FY2025
EPS	$0.10	−111%	FY2025
Gross margin	60%	n/a	FY2025
Operating margin	13%	n/a	FY2025
Net margin	4.8%	n/a	FY2025
ROE	−9.8%	n/a	FY2025
ROA	1.9%	n/a	FY2025
ROIC	7.3%	n/a	FY2025
Free cash flow	−$115M	−61%	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.